World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
115
Citations
72506
World Ranking
4440
National Ranking
2421

Overview

Zachary Goodman is affiliated with Inova Fairfax Hospital in the United States. Their primary field of study is Medicine, with a significant focus on Hepatology. Their research contributions span various subfields including Hepatology, Epidemiology, Surgery, Endocrinology, Diabetes and Metabolism, and Cell Biology.

The scientist's main research topics include:

  • Liver Disease Diagnosis and Treatment
  • Liver Diseases and Immunity
  • Liver Disease and Transplantation
  • Hepatitis C virus research
  • Liver physiology and pathology
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Diet, Metabolism, and Disease

Zachary Goodman has published extensively in several high-impact journals. Their frequent publication venues are:

  • Journal of Hepatology (33 publications)
  • Hepatology (9 publications)
  • Gastroenterology (6 publications)
  • Hepatology Communications (5 publications)
  • Clinical Gastroenterology and Hepatology (4 publications)

Among recent papers authored or co-authored by Goodman, notable works include:

  • "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials" (2020), published in Journal of Hepatology
  • "From NAFLD to MAFLD: Implications of a Premature Change in Terminology" (2020), published in Hepatology
  • "Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study" (2020), published in Hepatology
  • "Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH" (2020), published in Hepatology
  • "A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH" (2021), published in Hepatology

Collaborations feature prominently in Goodman's research activity. Frequent co-authors include:

  • Stephen A. Harrison
  • Zobair M. Younossi
  • Arun J. Sanyal
  • Quentin M. Anstee
  • Rohit Loomba

Best Publications

  • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

    Michael P. Manns;John G. McHutchison;Stuart C. Gordon;Vinod K. Rustgi

  • Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

    John G. Mchutchison;Stuart C. Gordon;Eugene R. Schiff;Mitchell L. Shiffman

  • Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

    Bruce R. Bacon;Stuart C. Gordon;Eric Lawitz;Patrick Marcellin

  • A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B

    Ting Tsung Chang;Robert G. Gish;Robert De Man;Adrian Gadano

  • Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

    Patrick Marcellin;Ting Tsung Chang;Seng Gee Lim;Myron J. Tong

  • Lamivudine as initial treatment for chronic hepatitis B in the United States.

    Jules L. Dienstag;Eugene R. Schiff;Teresa L. Wright;Robert P. Perrillo

  • Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

    Ching Lung Lai;Daniel Shouval;Anna S. Lok;Ting Tsung Chang

  • Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

    Thierry Poynard;John McHutchison;Michael Manns;Christian Trepo

  • Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

    Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting-Tsung Chang

  • Persistence of cccDNA During the Natural History of Chronic Hepatitis B and Decline During Adefovir Dipivoxil Therapy

    Bettina Werle-Lapostolle;Scott Bowden;Stephen Locarnini;Karsten Wursthorn;Karsten Wursthorn

  • Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

    Ting Tsung Chang;Yun Fan Liaw;Shun Sheng Wu;Eugene Schiff

  • Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

    Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting–Tsung Chang

  • Telbivudine versus lamivudine in patients with chronic hepatitis B.

    Ching-Lung Lai;Edward Gane;Yun-Fan Liaw;Chao-Wei Hsu

  • Pathologic Diagnosis of Early Hepatocellular Carcinoma: A Report of the International Consensus Group for Hepatocellular Neoplasia

    Masamichi Kojiro;Ian R. Wanless;Venancio Alves;Sunil Badve

  • Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C

    Thierry Poynard;Vlad Ratziu;Frédéric Charlotte;Zachary Goodman

  • Grading and staging systems for inflammation and fibrosis in chronic liver diseases

    Zachary D. Goodman

  • A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

    Karen L. Lindsay;Christian Trepo;Tobias Heintges;Mitchell L. Shiffman

  • Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B

    Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting-Tsung Chang

  • Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement.

    Richard G. Barr;Giovanna Ferraioli;Mark L. Palmeri;Zachary D. Goodman

  • Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis.

    Adrian M. di Bisceglie;Zachary D. Goodman;Kamal G. Ishak;Jay H. Hoofnagle

Frequent Co-Authors

Zobair M. Younossi
Zobair M. Younossi Inova Health System
Rohit Loomba
Rohit Loomba University of California, San Diego
Andrew J. Muir
Andrew J. Muir Duke University
Stephen H. Caldwell
Stephen H. Caldwell University of Virginia
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
Mitchell L. Shiffman
Mitchell L. Shiffman Bon Secours Health System
Kamal G. Ishak
Kamal G. Ishak Armed Forces Institute of Pathology
Quentin M. Anstee
Quentin M. Anstee Newcastle University
John G. McHutchison
John G. McHutchison Duke University
Arun J. Sanyal
Arun J. Sanyal Virginia Commonwealth University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean becoming a physician. Today, online programs open new doors across health fields, offering flexibility for students balancing work and family. For example, those interested in medical administration can pursue a healthcare administration degree to train for leadership roles within hospitals, clinics, and insurance companies.

If you are looking for alternatives to medical practice itself, consider programs specializing in vital support roles—like enrolling in accredited medical billing and coding schools with financial aid. This pathway can lead to a rewarding career in health information management, often without years of schooling or major exams.

For aspiring nurses, the admissions process might be easier than expected. Some schools no longer require standardized pre-admission testing. Learn more by asking: do you have to take the teas test to get into nursing school? This option can streamline your journey into the nursing profession.

Already a registered nurse? Fast-track your advancement with asn to fnp programs, which bridge associate’s degree nurses to a Master’s and prepare you to become a Family Nurse Practitioner.

Best Scientists Citing Zachary Goodman

Trending Scientists

Recently Published Articles